APR 27 2026
AstraZeneca — Saphnelo (anifrolumab) $AZN
for systemic lupus erythematosus
FDA approved AstraZeneca's Saphnelo Pen autoinjector for once-weekly subcutaneous self-administration in adult SLE patients.
About
Systemic lupus erythematosus is an autoimmune disease where the immune system mistakenly attacks healthy tissues, causing symptoms like joint pain, fatigue, and skin rashes that can flare unpredictably. Saphnelo (anifrolumab) is an antibody that blocks a specific immune signal called type I interferon, which is overactive in lupus and drives the immune system’s attack on the body. By calming this overactive pathway, Saphnelo may help reduce the frequency and severity of lupus flares, offering a potential way to manage this complex condition.
Pivotal trial
The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment regimen of anifrolumab versus placebo in Asian participants with active systemic lupus erythematosus (SLE).
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Saphnelo
- SAPHNELO shows strong sales growth and market potential for lupus treatment through 2034. - Pluang
- FDA approves Saphnelo Pen for at-home lupus treatment - Lupus News Today
- FDA approves AstraZeneca’s Saphnelo for SLE - Pharmaceutical Technology
- FDA approves AstraZeneca's Saphnelo Pen autoinjector in systemic lupus erythematosus - Manufacturing Chemist
- Saphnelo approved in the US for subcutaneous self-administration as a new autoinjector for the treatment of systemic lupus erythematosus - AstraZeneca